jeudi 11 juillet 2019

Onco Actu du 11 juillet 2019


2. ETIOLOGIE



Night Shift Work Classified as Probably Carcinogenic to Humans [ESMO]











Having fewer 'friendly vaginal bacteria' linked to ovarian cancer [NHS Choices]










2.11 ETIOLOGIE - ALIMENTATION



Are sugary drinks causing cancer? [BBC News]











Sugary Drinks Linked to Cancer Onset [NY Times]











Study finds possible link between sugary drinks and cancer [Reuters]











Sugar in fruit juice may raise risk of cancer, study finds [The Guardian]










2.7 ETIOLOGIE - OBÉSITÉ



Maternal obesity linked to childhood cancer [MedicalXpress]











3.1 PRÉVENTION - TABAC



Research Brief: Cigarettes marketed as “natural” and “organic” are loaded with nicotine and toxicants, just like other cigarettes [University of Minnesota]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Vape shops open in two UK hospitals to help smokers kick the habit [The Guardian]











How FDA is Regulating E-Cigarettes [FDA]










4.10 DÉP., DIAG. & PRONO. - POUMON



Multi-Gene Panel Testing Moderately Cost Effective for Lung Cancer Patients [Genome Web]











5. TRAITEMENTS



Therapeutic Strategies Based on Evolutionary Principles May Be Key to Improving Patient Outcomes [Moffitt Cancer Center]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Cancer biologists identify new drug combo [MIT]











An effort to map cancer’s weak spots is starting to reveal new drug targets [Broad Institute]










5.10 TRAITEMENTS - ESSAIS



Score! 'Good Pharma' ranking finds uptick in new drug data sharing and clinical trial transparency [Fierce Pharma]











Data sharing in clinical trials: keeping score [BMJ]










5.2 PHARMA



FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex [Fierce Biotech]











Nanobiotix Announces Publication Of Phase III Soft Tissue Sarcoma Data For First-In-Class NBTXR3 In The Lancet Oncology [Nanobiotix]











5.2.1 PHARMA - PARTENARIATS



Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155 [Mirati]











Amgen's KRAS success has other drugmakers eager to follow [Biopharma Dive]











5.2.3 PHARMA - ÉCONOMIE



Revolution Medicines snags $100M to attack RAS-mutated cancers [Fierce Biotech]











Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA promises ‘elevated’ new drug approvals, but warns of potential pitfalls: report [Fierce Pharma]










New drugs: where did we go wrong and what can we do better? [BMJ]










6. LUTTE CONTRE LES CANCERS



Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies [NCI]











6.1 OBSERVATION



Are doctors treating more thyroid cancer patients than necessary? [Science Daily]











6.11 PATIENTS



From biotech CEO to ‘expert patient:’ HPV awareness advocate Michael Becker dies [Fierce Biotech]











Every data point has a face: What Michael Becker taught us [STAT]











6.6 PUBLICATIONS



University of California loses access to new journal articles published by Elsevier after research access fight [STAT]











6.9 CONTROVERSES



Olfactory mucosa tumors: Another complication of stem cell treatments [Respectful Insolence]











Canada case highlights possible long-term risks of experimental stem cell therapy [STAT]